EyePoint Pharmaceuticals has bounced 11.6% this week to $14.38, yet the persistent weight of heavy short positioning and a notable shift in options sentiment means this recovery is happening against an unconvinced market backdrop.
The positioning picture is a study in contradictions. Short interest at nearly 19% of the free float — up around 6.5% over the past month to roughly 15.6 million shares — makes EYPT one of the more heavily shorted names in small-cap specialty biopharma. That short base has been quietly growing even as the stock pushed higher, which means bears have been adding conviction into strength. The borrow market tells a calmer supplementary story: cost to borrow has actually fallen sharply, down 22% on the week to just 0.4%, and availability is wide at roughly 600% of current short interest. Those numbers mean the lending pool is far from stressed — there are approximately six shares available to borrow for every one currently shorted — so there is no squeeze pressure building from the supply side. The contradiction is that shorts are growing, but doing so at minimal cost. Options traders, meanwhile, shifted tone more suddenly. The put/call ratio jumped from a range of roughly 1.03–1.06 before June 15 to 1.39 today — nearly two standard deviations above its 20-day average of 1.13. That is the most defensive options reading in several months and a marked change in character, coming precisely during the week the stock rallied hardest.
The Street broadly likes EyePoint but from a very different altitude than the current share price suggests it should. Guggenheim reiterated its Buy rating with a $68 target as recently as today, while RBC Capital trimmed its target modestly to $37 following Q1 results in May — both still pointing to what the consensus sees as substantial upside from current levels. That gap between $14.38 and targets clustered in the $30–$68 range reflects the deep uncertainty around pipeline execution rather than a difference of opinion on fundamentals. The bull case rests on DURAVYU and EYP-2301, with clinical trial enrollment that has reportedly outpaced comparable wet AMD programmes. The bear case is blunt: quarterly net revenue collapsed to $5.3 million from $9.5 million a year ago, R&D spending nearly doubled to $55.5 million, and the company remains firmly pre-revenue on its key programmes. The short score of 68.8 has been stable over the past two weeks rather than climbing, and the days-to-cover sits near 15 — meaningful but not extreme.
Institutional ownership adds an interesting dimension. The holder base is concentrated in specialist biotech funds. Suvretta Capital and Cormorant Asset Management each hold close to 10% of shares outstanding, and Commodore Capital entered with a fresh 4.25 million share position as recently as May. Federated Hermes added 733,000 shares in Q1. Against that, Adage Capital trimmed by 1.4 million shares over the same period. The net effect is a shareholder base dominated by specialist funds with high conviction on both sides — the kind of register that tends to amplify moves around catalysts.
The next earnings event is July 31. Prior results have delivered muted single-digit moves — down around 2.5% after Q1 and up 4.4% after the mid-June update — suggesting the stock has not been delivering the large binary swings typical of early-stage biopharma, at least recently. Peers OCUL and TRVI both gained 12–19% on the week, suggesting the broader ophthalmic/specialty biopharma cohort has been in favour, which gives EyePoint's rally some sector-level support rather than being purely idiosyncratic.
The setup heading into July 31 is therefore less about whether the short base is crowded — it is elevated but not acute from a lending perspective — and more about whether the growing put protection and rebuilding short interest reflect genuine clinical scepticism about the DURAVYU readout timeline, or simply cautious positioning ahead of a catalyst that the specialist holders clearly believe will resolve to the upside.
See the live data behind this article on ORTEX.
Open EYPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
